Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02333760 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Long Term Safety Follow up of Haematopoietic Stem Cell Gene Therapy for the Wiskott Aldrich Syndrome

Study acronym: WASFUP
StatusActive, Not Recruiting
PhasePhase 1/2
SponsorGenethon
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion dates: Dec 2027 to Oct 2032
    • Trial status: Recruiting to Active, Not Recruiting
    • Secondary endpoints: details revised at 3 of 3 entries
    • Site details revised at 2 of 2 sites
    v7
  2. Study title expanded, about 11 wordsv6
  3. Primary and study completion dates: Dec 2019 to Dec 2027v5
  4. 3 versions Re-verified since Oct 28, 2015, no change to tracked fieldsv2-v4
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Genethon
9 trials monitored
See all monitored trials
An open follow up study of patients enrolled in the Phase 1/2 clinical trial of haematopoietic stem cell gene therapy for the Wiskott-Aldrich Syndrome and treated with autologous CD34+ cells transduced with the w1.6\_hWASP\_WPRE (VSVg) lentiviral vector.
Trial Details
NCT Number NCT02333760
Lead Sponsor Genethon
Conditions
(from sponsor)		 Wiskott-Aldrich Syndrome
Related terms Wiskott-Aldrich Syndrome
Enrollment 10 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov